{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:57:34Z","timestamp":1790888254331,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Patients who were hospitalized with coronavirus disease 2019 (COVID-19) infection are at high risk of AKI and KRT, especially in the presence of CKD. The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial showed that in patients hospitalized with COVID-19, treatment with dapagliflozin versus placebo resulted in numerically fewer participants who experienced organ failure or death, although these differences were not statistically significant. We performed a secondary analysis of the DARE-19 trial to determine the efficacy and safety of dapagliflozin on kidney outcomes in the overall population and in prespecified subgroups of participants defined by baseline eGFR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      The DARE-19 trial randomized 1250 patients who were hospitalized (231 [18%] had eGFR &lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) with COVID-19 and cardiometabolic risk factors to dapagliflozin or placebo. Dual primary outcomes (time to new or worsened organ dysfunction or death, and a hierarchical composite end point of recovery [change in clinical status by day 30]), and the key secondary kidney outcome (composite of AKI, KRT, or death), and safety were assessed in participants with baseline eGFR &lt;60 and \u226560 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The effect of dapagliflozin versus placebo on the primary prevention outcome (hazard ratio, 0.80; 95% confidence interval, 0.58 to 1.10), primary recovery outcome (win ratio, 1.09; 95% confidence interval, 0.97 to 1.22), and the composite kidney outcome (hazard ratio, 0.74; 95% confidence interval, 0.50 to 1.07) were consistent across eGFR subgroups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      for interaction: 0.98, 0.67, and 0.44, respectively). The effects of dapagliflozin on AKI were also similar in participants with eGFR &lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (hazard ratio, 0.71; 95% confidence interval, 0.29 to 1.77) and \u226560 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (hazard ratio, 0.69; 95% confidence interval, 0.37 to 1.29). Dapagliflozin was well tolerated in participants with eGFR &lt;60 and \u226560 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The effects of dapagliflozin on primary and secondary outcomes in hospitalized participants with COVID-19 were consistent in those with eGFR below\/above 60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . Dapagliflozin was well tolerated and did not increase the risk of AKI in participants with eGFR below or above 60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.14231021","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T14:36:30Z","timestamp":1651847790000},"page":"643-654","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection"],"prefix":"10.2215","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct04350593","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04505774","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04381936","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J.L.","family":"Heerspink","sequence":"first","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"},{"name":"The George Institute for Global Health, Newtown, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo H.M.","family":"Furtado","sequence":"additional","affiliation":[{"name":"Academic Research Organization, Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"},{"name":"Instituto do Coracao do Hospital das Clinicas da FMUSP, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio","family":"Berwanger","sequence":"additional","affiliation":[{"name":"Academic Research Organization, Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary G.","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Martinez","sequence":"additional","affiliation":[{"name":"National University of C\u00f3rdoba, C\u00f3rdoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mukhtar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Experimental Medicine and Immunotherapeutics Division, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada"},{"name":"Department of Surgery and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-2208","authenticated-orcid":false,"given":"Samvel B.","family":"Gasparyan","sequence":"additional","affiliation":[{"name":"Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Tang","sequence":"additional","affiliation":[{"name":"Saint Luke's Mid America Heart Institute, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl L.","family":"Windsor","sequence":"additional","affiliation":[{"name":"Saint Luke's Mid America Heart Institute, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente C\u00e9s","family":"de Souza-Dantas","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, University Hospital Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mildren","family":"del Sueldo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinica de Especialidades, Villa Maria, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Frankel","sequence":"additional","affiliation":[{"name":"Cardiology, Maimonides Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Javaheri","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8628-5219","authenticated-orcid":false,"given":"Rafael A.","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Nephrology and Transplantation Service, Cl\u00ednica Privada V\u00e9lez Sarsfield, Postgraduate School of Nephrology, National University of C\u00f3rdoba, C\u00f3rdoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn","family":"Morse","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-1533","authenticated-orcid":false,"given":"Marco","family":"Mota-Gomes","sequence":"additional","affiliation":[{"name":"Centro Universit\u00e1rio Cesmac\/Hospital do Cora\u00e7\u00e3o de Alagoas, Macei\u00f3, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Shemin","sequence":"additional","affiliation":[{"name":"Division of Kidney Diseases and Hypertension, Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo Louren\u00e7o","family":"Silva","sequence":"additional","affiliation":[{"name":"Centro Integrado de Pesquisas, Hospital de Base-S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 do Rio Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Pereira","family":"Tognon","sequence":"additional","affiliation":[{"name":"Academic Research Organization, Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Twahirwa","sequence":"additional","affiliation":[{"name":"Diabetes and Endocrinology Institute, Doctors Hospital at Renaissance, Edinburg, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Buenconsejo","sequence":"additional","affiliation":[{"name":"Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Esterline","sequence":"additional","affiliation":[{"name":"Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oscarsson","sequence":"additional","affiliation":[{"name":"Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Ambery","sequence":"additional","affiliation":[{"name":"Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, Newtown, NSW, Australia"},{"name":"Saint Luke's Mid America Heart Institute, Kansas City, Missouri"},{"name":"School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/14787210.2020.1822737","article-title":"COVID-19 and cardiac injury: Clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up","volume":"19","author":"Tajbakhsh","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S2213-8587(20)30271-0","article-title":"Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study","volume":"8","author":"Holman","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jclinpath-2020-207023","article-title":"High burden of acute kidney injury in COVID-19 pandemic: Systematic review and meta-analysis","volume":"74","author":"Oliveira","year":"2021","journal-title":"J Clin Pathol"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1681\/ASN.2020060897","article-title":"AKI treated with renal replacement therapy in critically ill patients with COVID-19","volume":"32","author":"Gupta","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1681\/ASN.2020050615","article-title":"AKI in hospitalized patients with COVID-19","volume":"32","author":"Chan","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/ki.2008.516","article-title":"Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease","author":"Cachofeiro","year":"2008","journal-title":"Kidney Int Suppl"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"E2359","DOI":"10.3390\/jcm9082359","article-title":"Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: A 2020 update","volume":"9","author":"Roumeliotis","year":"2020","journal-title":"J Clin Med"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical recommendations for the management of diabetes in patients with COVID-19","volume":"8","author":"Bornstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/dom.14296","article-title":"Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study","volume":"23","author":"Kosiborod","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1177\/0962280220942558","article-title":"Adjusted win ratio with stratification: Calculation methods and interpretation","volume":"30","author":"Gasparyan","year":"2021","journal-title":"Stat Methods Med Res"},{"issue":"Suppl 1","key":"B20-20241015","first-page":"S111","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes 2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/ejhf.2026","article-title":"Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s13054-020-03009-y","article-title":"Incidence of acute kidney injury in COVID-19 infection: A systematic review and meta-analysis","volume":"24","author":"Chen","year":"2020","journal-title":"Crit Care"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.14231021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:00Z","timestamp":1786369500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.14231021"}},"subtitle":["An Analysis of the DARE-19 Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.14231021","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"2021-10-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}